Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
LOC
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1
EP3013362B1
DENDRITIC CELL ASGPR TARGETING IMMUNOTHERAPEUTICS FOR MULTIPLE SCLEROSIS
Publication/Patent Number: EP3013362B1 Publication Date: 2021-08-04 Application Number: 14817259.6 Filing Date: 2014-06-27 Inventor: Oh, Sangkon   Zurawski, Gerard   Assignee: Baylor Research Institute   IPC: A61P35/00
2
EP3310811B1
ANTI-CD3 ANTIBODIES AND METHODS OF USE
Publication/Patent Number: EP3310811B1 Publication Date: 2021-06-16 Application Number: 16728531.1 Filing Date: 2016-05-31 Inventor: Lee, Chingwei Vivian   Dennis, Mark S.   Fuh, Germaine   Assignee: Genentech, Inc.   IPC: A61P35/00
3
CN113164516A
靶向突变型p53基因的硼酸铅纳米颗粒在癌症治疗中的用途及这些纳米颗粒的制备方法
Public
Publication/Patent Number: CN113164516A Publication Date: 2021-07-23 Application Number: 201880098984.8 Filing Date: 2018-11-08 Inventor: F·萨欣   P·n·塔斯利   O·k·基尔巴斯   T·b·哈亚尔   B·t·博兹库尔特   B·布尔布尔   S·贝亚兹   Assignee: 耶迪特普大学   IPC: A61K33/241 Abstract: 本发明涉及纳米级硼酸铅化合物由于它们对p53突变型乳腺癌细胞系T47D的选择性抗癌活性而用于治疗目的的用途。本发明的合成纳米级硼酸铅的方法包括以下步骤:用氢氧化钠和硼酸制备硼酸盐缓冲溶液,通过搅拌将硝酸铅(和优选PEG)溶解在蒸馏水中,将硼酸盐缓冲溶液与硝酸铅(和优选PEG)溶液混合,用蒸馏水洗涤所得溶液并干燥以除去杂质。
4
US2021220369A1
HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE
Publication/Patent Number: US2021220369A1 Publication Date: 2021-07-22 Application Number: 17/058,982 Filing Date: 2019-03-14 Inventor: Banoglu, Erden   Caliskan, Burcu   Sahin, Ozgur   Lengerli, Deniz   Akbulut, Ozge   Assignee: A2A Pharmaceuticals, Inc.   OncoCube Therapeutics LLC   IPC: A61K31/5377 Abstract: The present disclosure relates to 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine and methods of use thereof.
5
CN111053778B
咪唑并喹唑啉类衍生物及其盐制备PIM1酶抑制剂的应用、PIM1酶抑制剂及其应用
Grant
Publication/Patent Number: CN111053778B Publication Date: 2021-07-23 Application Number: 201911070051.0 Filing Date: 2019-11-05 Inventor: 姚若斯   高剑   Assignee: 徐州医科大学   IPC: A61K31/519 Abstract: 本发明属于药物化学和药物治疗学技术领域,尤其涉及咪唑并喹唑啉类衍生物及其盐制备PIM1酶抑制剂的应用、PIM1酶抑制剂及其应用。本发明提供的咪唑并喹唑啉类衍生物对PIM1酶具有明显的抑制活性,该咪唑并喹唑啉类衍生物可以应用于制备PIM1酶抑制剂,进而可以用于多发性骨髓瘤细胞增殖抑制剂和抗多发性骨髓瘤药物的制备中。
6
EP3845231A1
THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
Publication/Patent Number: EP3845231A1 Publication Date: 2021-07-07 Application Number: 19856279.5 Filing Date: 2019-08-28 Inventor: Irie, Hiroki   Fujioka, Yayoi   Assignee: Taiho Pharmaceutical Co., Ltd.   IPC: A61K31/519 Abstract: Provided is an anti-tumor agent for the treatment of a HER2-positive tumor that is tolerant to other anti-tumor agents or an intractable HER2-positive tumor. More specifically provided is a therapeutic agent for a HER2-positive tumor that is tolerant to other anti-tumor agents or an intractable HER2-positive tumor, which contains a pyrazolo[3,4-d]pyrimidine compound or a salt thereof as an active ingredient.
7
EP3845251A1
LINKER CONTAINING ARYLNITRO, ANTIBODY-DRUG CONJUGATE CONTAINING LINKER AND USE OF LINKER
Publication/Patent Number: EP3845251A1 Publication Date: 2021-07-07 Application Number: 19853328.3 Filing Date: 2019-08-28 Inventor: Zhou, Xinbo   Wang, Yanming   Li, Song   Zhong, Wu   Fan, Shiyong   Xiao, Dian   Xiao, Junhai   Zheng, Zhibing   Li, Xingzhou   Xie, Yunde   Cao, Ruiyuan   Wang, Xiaokui   Assignee: Academy of Military Medical Sciences   IPC: A61K47/68 Abstract: The present application relates to a linker containing arylnitro, an antibody-drug conjugate the linker and use of the linker, as well as a pharmaceutical composition comprising the antibody-drug conjugate and use of the antibody-drug conjugate for treatment and/or prevention of a disease.
8
CN112439021A
一种治疗癌症的药方
Substantial Examination
Publication/Patent Number: CN112439021A Publication Date: 2021-03-05 Application Number: 201910878957.9 Filing Date: 2019-09-04 Inventor: 姜瑞生   Assignee: 姜瑞生   IPC: A61K36/8905 Abstract: 一种治疗癌症的药方,它主要成分由以下重量份组成:野猕猴桃根12g;肉灵芝10g;生黑牵牛10g;生香附子10g;生广木香10g;岩黄莲10g;红豆杉8;半枝莲15g;八月瓜10g;路边黄5g。
9
US2021213100A1
NEUREGULIN FOR THE TREATMENT AND/OR PREVENTION OF TUMORS OF THE NERVOUS SYSTEM
Publication/Patent Number: US2021213100A1 Publication Date: 2021-07-15 Application Number: 15/999,851 Filing Date: 2017-04-19 Inventor: Schulz, Alexander   Morrison, Helen   Assignee: LEIBNIZ-INSTITUT FUR ALTERSFORSCHUNG-FRITZ-LIPMAN- INSTITUT E.V. (FLI)   IPC: A61K38/18 Abstract: The invention relates to a polypeptide, wherein said polypeptide comprises or consists of an EGF-like domain of a neuregulin protein. The invention more over relates to a nucleic acid encoding for said polypeptide, a gene therapy vector comprising said nucleic acid and genetically modified cells expressing said polypeptide. The invention relates to the medical use of said polypeptide, said nucleic acid, said gene therapy vector or said cell for the treatment of tumours of the nervous system, in particular for the treatment of tumours of the cranial or peripheral nerves, tumours associated with neurofibromatosis, schwannomas, neurofibromas and malignant nerve sheath tumours.
10
CN107362158B
马钱苷元在制备抗肿瘤药物中的用途
Grant Assignment
Publication/Patent Number: CN107362158B Publication Date: 2021-07-20 Application Number: 201610309487.0 Filing Date: 2016-05-11 Inventor: 张贵民   姚景春   李光艳   王恩力   Assignee: 山东新时代药业有限公司   IPC: A61K31/352 Abstract: 本发明属于医药领域,涉及马钱苷元在制备抗肿瘤药物中的用途,在此所述的肿瘤具体涉及哺乳动物胃癌、肝癌、食管癌、结直肠癌、胰腺癌、肺癌、头颈癌、白血病、恶性淋巴瘤、前列腺癌、乳腺癌、脑胶质瘤、胆管癌、黑色素瘤、肾癌、卵巢癌、子宫内膜癌、宫颈癌,更具体为人胃癌、人肝癌、人食管癌、人结直肠癌、人胰腺癌、人肺癌、人头颈癌、人白血病、人恶性淋巴瘤、人前列腺癌、人乳腺癌、人脑胶质瘤、人胆管癌、人黑色素瘤、人肾癌、人卵巢癌、人子宫内膜癌、人宫颈癌。通过体内外试验发现马钱苷元对上述各种肿瘤均具有良好的抑制作用,显示出很好的抗肿瘤生长活性,具有很大的开发为抗肿瘤药物的潜能。
11
CN110201015B
锈腐病人参提取物在制备用于治疗肿瘤的药物中的应用
Grant
Publication/Patent Number: CN110201015B Publication Date: 2021-08-06 Application Number: 201910498898.2 Filing Date: 2019-06-11 Inventor: 王作斌   胡婧   陈玉娟   焦洁   王莹   高明燕   卢征程   杨帆   胡翠华   宋正勋   Assignee: 长春理工大学   IPC: A61K36/258 Abstract: 本发明涉及药物制剂技术领域,具体涉及锈腐病人参提取物在制备用于治疗肿瘤的药物中的应用。本发明提供锈腐病人参提取物在制备治疗肿瘤的药物中的应用。本发明创造性地发现锈腐病人参提取物具有抗癌活性,与正常人参提取物相比,从锈腐病人参中提取得到的提取物对多种癌细胞均表现出更强的抗癌活性,能够有效诱导癌细胞凋亡并抑制癌变细胞增殖,可作为广谱的抗癌活性物质,用于制备抗癌药物,为治疗癌症提供新的用药方案。
12
CN112933098A
一种灰黄霉素四唑衍生物在制备抗肿瘤药物中的应用
Substantial Examination
Publication/Patent Number: CN112933098A Publication Date: 2021-06-11 Application Number: 202110169678.2 Filing Date: 2021-02-07 Inventor: 孟国梁   赵育   杨圣菊   朱力   Assignee: 南通大学   IPC: A61K31/55 Abstract: 本发明属于药物化学和药理学技术领域,涉及一种灰黄霉素四唑衍生物在制备抗肿瘤药物中的应用,该灰黄霉素四唑衍生物具有式(I)所示化学结构式,由灰黄霉素与叠氮钠在三氟乙酸中发生重排反应得到四唑中间体1。然后四唑中间体1在二氯甲烷中用三溴化硼脱除甲基,得到四唑中间体2;四唑中间体2与溴代烃,在碳酸钾存在下,在N,N‑二甲基甲酰胺中进行取代反应,得到相应的灰黄霉素四唑衍生物。本发明得到的具有灰黄霉素四唑衍生物具有较强的抗肿瘤活性,可用于制备抗肿瘤药物。
13
CN112933099A
吖庚因喹唑啉类化合物在制备治疗乳腺癌药物中的应用
Substantial Examination
Publication/Patent Number: CN112933099A Publication Date: 2021-06-11 Application Number: 202110178540.9 Filing Date: 2021-02-09 Inventor: 王叶凡   饶国武   靳浩   Assignee: 浙江工业大学   IPC: A61K31/55 Abstract: 本发明公开了一类吖庚因喹唑啉类化合物在制备预防或治疗人乳腺癌药物中的应用,其对抑制人乳腺癌细胞MCF‑7和MDA‑MB‑231活性具有显著效果。
14
CN108578464B
一种鸡血藤提取物在制备抗肿瘤药物中的应用
Grant
Publication/Patent Number: CN108578464B Publication Date: 2021-06-11 Application Number: 201810538736.2 Filing Date: 2018-05-30 Inventor: 朱晓新   李琦   孙立东   王娅杰   杨庆   陈颖   李玉洁   翁小刚   蔡维艳   Assignee: 中国中医科学院中药研究所   IPC: A61K36/486 Abstract: 本发明涉及一种鸡血藤提取物在制备抗肿瘤药物中的应用,其中所述鸡血藤提取物选自:鸡血藤水提取物,鸡血藤乙酸乙酯提取物,鸡血藤正丁醇提取物。其中所述鸡血藤提水提取物,制备方法如下:鸡血藤70kg,每次用5倍量蒸馏水回流提取,共2次,每次2h,合并后减压浓缩,75℃蒸汽真空干燥7h。获得鸡血藤水提取物6kg,得到水提取物。
15
CN113018422A
抑制乳腺癌细胞增殖的方法和蛋白精氨酸甲基转移酶7的应用
Substantial Examination
Publication/Patent Number: CN113018422A Publication Date: 2021-06-25 Application Number: 201911250733.X Filing Date: 2019-12-09 Inventor: 刘扬   耿鹏宇   Assignee: 中国科学院大连化学物理研究所   IPC: A61K38/45 Abstract: 本发明公开蛋白精氨酸甲基转移酶PRMT7在乳腺癌肿瘤发生中的应用。本发明证明PRMT7能够抑制乳腺癌细胞的增殖,诱导细胞周期停滞。过表达PRMT7能够抑制小鼠的成瘤能力。此发明有助于揭示PRMT7作为乳腺癌肿瘤发生早期诊断的分子靶标。
16
CN112972479A
Rho抑制剂盐酸法舒地尔的新用途
Substantial Examination
Publication/Patent Number: CN112972479A Publication Date: 2021-06-18 Application Number: 202110248564.7 Filing Date: 2021-03-08 Inventor: 刘喆   李国利   雷新月   陈可欣   马振毅   Assignee: 天津医科大学   IPC: A61K31/551 Abstract: 本发明涉及一种Rho抑制剂盐酸法舒地尔在作为或制备卵巢癌的药物方面中的应用。本发明通过Rho抑制剂的干预作用来提高A/A基因型卵巢癌患者的治疗效果,减小传统方法放疗化疗对人体的危害。
17
US2021244814A1
COMBINATION OF METFORMIN AND CYCLOPHOSPHAMIDE AS AN ADJUVANT IN CANCER IMMUNOTHERAPY
Publication/Patent Number: US2021244814A1 Publication Date: 2021-08-12 Application Number: 17/049,435 Filing Date: 2019-04-25 Inventor: Van, Den Eynde Benoît   Finisguerra, Veronica   Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAIN   IPC: A61K39/395 Abstract: A combination including metformin and cyclophosphamide for use with an immunotherapy in the treatment of a solid cancer. In particular, the combination including metformin and cyclophosphamide is used as an adjuvant for an immunotherapy. More specifically, a combination including metformin and cyclophosphamide for use with an adoptive cell therapy, with a therapeutic vaccine, with a checkpoint inhibitor therapy or with a T-cell agonist therapy, preferably with an adoptive cell therapy or a checkpoint inhibitor therapy, in the treatment of a solid cancer.
18
CN109010829B
一种具有光热化疗双功能的自组装卟啉纳米材料及其制备方法和应用
Grant
Publication/Patent Number: CN109010829B Publication Date: 2021-01-15 Application Number: 201811196603.8 Filing Date: 2018-10-15 Inventor: 白锋   王孝   王杰菲   钟永   王静菡   Assignee: 河南大学   IPC: A61K41/00 Abstract: 本发明提供了一种具有光热化疗双功能的自组装卟啉纳米材料及其制备方法和应用,属于材料学与生物纳米医药技术领域。本发明将四吡啶基金卟啉和氯仿混合,得到金卟啉氯仿溶液;将所述金卟啉氯仿溶液在乳化剂的作用下造乳,去除氯仿,剩余的溶液立即冷却,得到自组装卟啉纳米材料溶液。本发明制备的自组装卟啉纳米材料将具有化疗效果的金卟啉金属化,通过自组装的方法实现纳米化,得到的自组装卟啉纳米材料不仅具有化疗效果还具备光热性能。实验证明本发明制备的自组装卟啉纳米材料具有优异光热化疗性能,能够在制备光热‑化疗联合治疗癌症的药物中的应用。
19
US2021008053A1
COMBINATION THERAPIES FOR TREATING CANCER
Publication/Patent Number: US2021008053A1 Publication Date: 2021-01-14 Application Number: 16/614,131 Filing Date: 2018-05-18 Inventor: Sun, Kaiming   Wang, Jing Yu   Wang, Zebin   Assignee: TESARO, INC.   IPC: A61K31/4439 Abstract: The present invention provides methods of treatment for cancer(s) through combination therapy with an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling and an agent that regulates activity within the tumor microenvironment.
20
US2021085736A1
IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER
Publication/Patent Number: US2021085736A1 Publication Date: 2021-03-25 Application Number: 17/048,297 Filing Date: 2019-04-19 Inventor: Chen, Zhiwei   Tan, Zhiwu   Assignee: The University of Hong Kong   IPC: A61K35/768 Abstract: The invention pertains to methods of treating a cancer in a subject by administering to the subject a combination of an oncolytic virus and a therapy that induces depletion of tumor-induced bone marrow myeloid-derived suppressor cells of polymorphonuclear type (PMN-MDSCs). In certain preferred embodiments, the oncolytic virus is a replication incompetent modified vaccinia TianTan (MVTT) virus having a deletion of the viral M1L-K2L genes. In other preferred embodiments, the therapy that induces depletion of tumor-induced PMN-MDSCs comprises administering an antibody against Ly6G, for example 1A8. The cancer therapies of the invention can be administered in combination with one or more additional anti-cancer therapies. Preferred additional anti-cancer therapy is an immunotherapy, such as administering a check-point inhibitor.
Total 500 pages